ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

March 9, 2022

The Centers for Medicare & Medicaid Services (CMS) announced that it will apply the Merit-based Incentive Payment System (MIPS) automatic extreme and uncontrollable circumstances (EUC) policy to all individual Merit-based Incentive Payment System (MIPS) eligible clinicians for the 2021 performance period.

March 8, 2022

The College of American Pathologists (CAP) and the American Society of Clinical Oncology (ASCO) hosted a virtual Immune Checkpoint Inhibition (ICI) Predictive Factor Summit to bring together stakeholders from the U.S. Food and Drug Administration (FDA), Centers for Medicare and Medicaid Services (CMS), National Institutes of Health (NIH), health insurance organizations, pharmaceutical companies, in vitro diagnostics manufacturers, and patient advocate organizations.

March 8, 2022

Marking International Women’s Day, ASCO and City Cancer Challenge Foundation (C/Can) are announcing their Leadership Programme for Women in Oncology, which seeks to address the specific challenges and barriers faced by women leaders in oncology and aims to strengthen leadership mindsets and skills of women working to improve access to equitable, quality cancer care in C/Can cities.

March 7, 2022

The Association for Clinical Oncology (ASCO) submitted comments in response to the Centers for Medicare & Medicaid Services’ (CMS) Contract Year 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit Programs proposed rule. The rule proposes changes to advance the administration’s efforts to improve consumer protections, reduce disparities, and improve health equity in the MA and Part D programs.

March 7, 2022

On March 4, 2022, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting.

March 2, 2022

ASCO stands with our Ukrainian members, the worldwide oncology community, and healthcare providers around the globe in condemning Russia’s unprovoked war on Ukraine. We call for an immediate cessation of these hostilities and demand full protection and safety for all Ukrainian patients, healthcare workers, and medical facilities.

March 1, 2022

The Association for Clinical Oncology (ASCO) sent a letter to members of the U.S. House of Representatives and U.S. Senate endorsing the Provider Relief Fund Improvement Act (H.R. 5963/S. 3611).

March 1, 2022

The Association for Clinical Oncology (ASCO), along with more than 20 other stakeholder groups, sent a letter to congressional leadership urging lawmakers in both chambers to pass legislation this year to help radiation therapy clinics continue to provide potentially life-saving care to patients with cancer.

March 1, 2022

The Association for Clinical Oncology (ASCO) joined with more than 100 organizations to urge Congress to support President Biden’s reinvigorated Cancer Moonshot and to allocate funding to support the initiative.

March 1, 2022

On February 28, 2022, the Food and Drug Administration approved ciltacabtagene autoleucel (CARVYKTI, Janssen Biotech, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody.

February 18, 2022

The Association for Clinical Oncology (ASCO) is calling on Congress to continue their bipartisan support of federally funded research. Robust, sustained, and predictable funding growth for the National Institutes of Health (NIH) and the National Cancer Institute (NCI) baseline budgets are critical in advancing our nation’s work towards combating, and ultimately curing, diseases like cancer.

February 15, 2022

The Association for Clinical Oncology (ASCO) congratulates Robert M. Califf, MD, on his confirmation by the United States Senate to serve as the next Commissioner of the U.S. Food and Drug Administration (FDA). 

February 11, 2022

The Association for Clinical Oncology sent comments to leadership of the United States Senate Committee on Health, Education, Labor, and Pensions (HELP) regarding the Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act (PREVENT Pandemics Act), which aims improve the nation’s public health and medical preparedness systems, in addition to improving the U.S. healthcare system more broadly.

February 2, 2022

The Association for Clinical Oncology (ASCO) applauds President Biden for his decision to relaunch the Cancer Moonshot with ambitious and worthy goals of reducing the death rate from cancer and improving the experience of patients and families living with cancer.
 

February 1, 2022

World Cancer Day, held annually on February 4, is a global initiative led by the Union for International Cancer Control (UICC). This year’s event calls on the oncology community to “close the care gap,” with a focus on recognizing and understanding the inequities in cancer care and working to address them.

Pages